AstraZeneca: Truqap Plus Faslodex Approved In US For HR Breast Cancer

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that the U.S. Food and Drug Administration or FDA has approved its Truqap (capivasertib) in combination with Faslodex (fulvestrant) to treat patients with advanced hormone receptor or HR-positive breast https://www.nasdaq.com/articles/astrazeneca:-truqap-plus-faslodex-approved-in-us-for-hr-breast-cancer